Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.
about
Biological markers of amyloid beta-related mechanisms in Alzheimer's diseaseThe immunotherapy of Alzheimer's diseaseAutoantibodies in Alzheimer's disease: potential biomarkers, pathogenic roles, and therapeutic implicationsLead exposure increases levels of β-amyloid in the brain and CSF and inhibits LRP1 expression in APP transgenic miceIncreased β-amyloid deposition in Tg-SWDI transgenic mouse brain following in vivo lead exposurePrion peptide uptake in microglial cells--the effect of naturally occurring autoantibodies against prion proteinAmyloid beta-protein assembly as a therapeutic target of Alzheimer's disease.Inherent anti-amyloidogenic activity of human immunoglobulin gamma heavy chainsAnti-amyloidogenic activity of IgGs contained in normal plasmaAmyloid-beta immunotherapy for Alzheimer's diseaseA critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease.Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults.Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's diseaseA human monoclonal IgG that binds aβ assemblies and diverse amyloids exhibits anti-amyloid activities in vitro and in vivo.Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.Intravenous immunglobulin binds beta amyloid and modifies its aggregation, neurotoxicity and microglial phagocytosis in vitro.ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjectsBeta-amyloid auto-antibodies are reduced in Alzheimer's disease.C/T conversion alters interleukin-1A promoter function in a human astrocyte cell line.IgG Conformer's Binding to Amyloidogenic Aggregates.Epitope Fingerprinting for Recognition of the Polyclonal Serum Autoantibodies of Alzheimer's Disease.The immune system, amyloid-beta peptide, and Alzheimer's disease.Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia.Naturally occurring autoantibodies interfere with β-amyloid metabolism and improve cognition in a transgenic mouse model of Alzheimer's disease 24 h after single treatment.Present and prospective clinical therapeutic regimens for Alzheimer's disease.Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients.Increased Number of Plasma B Cells Producing Autoantibodies Against Aβ42 Protofibrils in Alzheimer's Disease.Evidence for prion-like mechanisms in several neurodegenerative diseases: potential implications for immunotherapyPharmacotherapeutic targets in Alzheimer's diseaseCan Alzheimer disease be prevented by amyloid-beta immunotherapy?Amyloid-β plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound.Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease.Antibody-based therapy in Alzheimer's disease.Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.Immunotherapy for Alzheimer disease: the challenge of adverse effects.Alzheimers disease: review of emerging treatment role for intravenous immunoglobulins.Immunomodulation and AD--down but not out.Should development of Alzheimer's disease-specific intravenous immunoglobulin be considered?
P2860
Q24622136-813A0C4A-8DEA-41FE-9966-34649AB97712Q24804900-9FBBD14B-1085-451B-BD8A-9162DA45C634Q26740418-586B27E1-0F0D-458A-8F24-D0423B855549Q28385932-63E04CBD-BF60-446E-8C6C-754180963A37Q28389213-921519E0-980F-46C4-9E08-757E81EC980DQ28534389-70215C08-9835-49B6-8D4C-6F21C68B6F56Q33392254-0CD239D3-8513-4429-A508-78535DBEC881Q33569608-08335BD4-4A82-40AF-AF13-10AA5D536EB9Q33903503-CB416421-F04B-4A21-B62D-15B85B74BAA8Q33954737-C8AD1224-E583-45EB-AB3A-62537F10C6D4Q34376103-FA395A6C-B9FF-4FE9-A37B-A99A0BF91ED9Q34413715-9C2BD96E-7C2F-4B8E-B100-480B0F2009A2Q34419295-CF353F86-6677-4926-940C-6A2F606E9BAFQ34473306-2998F91A-413F-4A20-8279-2EF4699BB5BAQ34500145-70D298CC-1C05-4A6F-9618-3ECDC3B753C7Q34733689-2DDF4668-338D-423D-9C03-982E2F8C5682Q35184148-4DFE9C14-2CAE-46F9-9FAE-706E703C6876Q35541293-E2125372-B3EE-4AB1-86E7-F0D49345D7BBQ35748268-5EEBE5C0-E958-415A-855B-2FDD9DDE5E4BQ35772596-FB754773-86FF-4579-9EFB-AA44C730A22EQ35791399-78E8C6D5-4F33-4AC5-99E0-FDB9D5981E8CQ36121068-2A0BEBF6-CC98-4BFB-8A7A-C27567B4543CQ36689356-2912A190-C124-4D00-82A7-41D9CE995EDFQ36764469-3DA147C9-BE7B-4507-9E2C-8BB53BDD1956Q36876447-291CDFDD-AAD2-43BE-8033-364834939EC1Q37024947-34206175-7411-4C64-ADDC-EC806AA0E516Q37044228-3AC12617-0DF2-4AD2-B60B-E3890B68C658Q37280507-F2F7A151-2713-4E3D-A354-C8D87F7CE791Q37295067-052164A4-8DCE-4E75-A5C5-C53C2D600999Q37688886-FCE93AFA-2148-445E-B989-72B99D901916Q37725032-C84113A7-6FAF-45F8-993E-3EA28ADFE125Q37773826-89EDEAF7-2497-4996-9554-0BBE9EA65490Q37810956-96C32388-EBF5-4F02-BB11-0AD58D2C5762Q37831912-6B0B6375-DA2D-4F73-99CB-CB3C64C61137Q37979840-C0431EE1-00F1-4090-A085-92A9A11CEC27Q37984574-E9D7233D-F531-4081-9E05-5AB17F8EE22CQ38023156-77137CA3-D413-4A82-9F40-723FBC20AFE0Q38122150-83B6C808-D401-462F-A378-E011F9433C3BQ38208226-D3D92665-CB5B-4B9D-852E-AFD356157F47Q38283308-6B272EB9-2E71-4B89-AE51-C1347609CBEC
P2860
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@en
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@nl
type
label
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@en
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@nl
prefLabel
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@en
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@nl
P2093
P356
P1433
P1476
Human anti-beta-amyloid antibo ...... amyloid-induced neurotoxicity.
@en
P2093
Liming Zhao
Martin Farlow
Norbert Sommer
Richard Dodel
Yansheng Du
Zhizhong Ma
P304
P356
10.1093/BRAIN/AWG191
P407
P577
2003-06-23T00:00:00Z